Hanmi Pharmaceutical's Partner Spectrum Receives FDA Approval for New Drug Treating Neutropenia

Published 13 Sep.2022 08:25(KST)

[Asia Economy Reporter Minji Lee] Hanmi Pharmaceutical announced on the 13th that its partner, Spectrum, has received approval from the U.S. Food and Drug Administration (FDA) for the new drug "Rol Jedon" for the treatment of neutropenia.

Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

"Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
"I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
"To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
"How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces

Rol Jedon is a long-acting granulocyte colony-stimulating factor (G-CSF) developed to reduce the duration of severe neutropenia in patients undergoing cytotoxic chemotherapy. Following the U.S. approval, it is scheduled to be launched within this year.

한글 기사 보기

This content was produced with the assistance of AI translation services.